Dyadic International, Inc.
DYAIHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeDyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. At a $53.6M market cap, Dyadic International, Inc. ranks as a micro-cap company within healthcare. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Market Cap
$53.6M
Beta
1.15
P/E (TTM)
—
P/E (Fwd)
-4.59
EPS (TTM)
$-0.26
EPS (Fwd)
$-0.32
ROE
-2826.9%
ROA
-56.2%
Cash
$5.6M
Total Debt
$5.1M
Free CF
-$4.2M
52W Change
50.0%
Annual Financials
Cash vs Debt
Where DYAI stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, DYAI finished 44.05% above its 150-day moving average ($0.84) and 35.96% above its 200-day moving average ($0.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DYAI overbought or oversold?
At the July 15, 2026 close, DYAI's RSI(14) was 71.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $5.6M in cash and $5.1M in debt, DYAI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$4.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -2826.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $2.9M (2022) to $1.2M (2025), a 58% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DYAI.